Bioxodes
Bioxodes develops an innovative pipeline in thrombo-inflammation with BIOX-101 as its lead candidate. The drug has a unique mechanism of action targeting neutrophils and coagulation factors (FXIIa, FXIa) for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients.
Key People
Marc Dechamps - Chief Executive Officer